BETHESDA, Md., April 19 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.
“Data presented at AACR this year demonstrates the versatility of the BiTE antibody platform,” said Patrick Baeuerle, Ph.D., Micromet’s Senior Vice President, Chief Scientific Officer. “The breadth and potency of product candidates developed utilizing our next-generation technology give us confidence that BiTE antibodies have the potential to significantly impact the way cancer is treated.”
Abstracts can be accessed through the AACR website, www.aacr.org. All posters will be accessible from Micromet’s website at www.micromet-inc.com after they are presented.
About Micromet
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com
CONTACT: Jennifer Neiman, Director, Corporate Communications, Micromet,
Inc., +1-240-235-0246, Jennifer.neiman@micromet-inc.com
Web site: http://www.micromet-inc.com/
